MGMA NAMES AKASH MADIAH AS CHIEF OPERATING OFFICER AND ANDREW SWANSON AS CHIEF REVENUE OFFICER
DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know
DaVita Price Target Raised to $150.00/Share From $139.00 by TD Cowen
TD Cowen Maintains Hold on DaVita, Raises Price Target to $150
DaVita Analyst Ratings
These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Reasonably Well
Express News | DaVita Inc : TD Cowen Raises Target Price to $150 From $139
TD Cowen Initiates DaVita(DVA.US) With Hold Rating, Announces Target Price $150
Balanced Outlook: Hold Rating on DaVita Amid Valuation and Regulatory Uncertainties
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
What to Expect From DaVita's Q2 2024 Earnings Report
Express News | DaVita Shares Down 1.4% in Volume Spike After Reaching Agreement With Justice Department to Resolve Kickback Allegations
Express News | U.S. Justice Department Says DaVita to Pay Over $34 Million to Resolve Allegations of Illegal Kickbacks
Express News | DaVita To Pay Over $34M To Settle Illegal Kickback Allegations
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 With a Remarkable 37.2% CAGR, According to Straits Research
Express News | DaVita and Fresenius Shares Are Trading Lower Following a Report Suggesting the FTC Is Investigating the Companies
Express News | DaVita Shares Fall 2.6% After Report That US FTC Is Investigating Co Over Allegations of Illegally Thwarting Smaller Competitors
No Data